| Cell sensitivity assays: the MTT assay J Van Meerloo, GJL Kaspers, J Cloos Cancer cell culture: methods and protocols, 237-245, 2011 | 2768 | 2011 |
| Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party GJ Schuurhuis, M Heuser, S Freeman, MC Béné, F Buccisano, J Cloos, ... Blood, The Journal of the American Society of Hematology 131 (12), 1275-1291, 2018 | 1107 | 2018 |
| Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features M Kool, J Koster, J Bunt, NE Hasselt, A Lakeman, P Van Sluis, D Troost, ... PloS one 3 (8), e3088, 2008 | 839 | 2008 |
| Molecular minimal residual disease in acute myeloid leukemia M Jongen-Lavrencic, T Grob, D Hanekamp, FG Kavelaars, A Al Hinai, ... New England Journal of Medicine 378 (13), 1189-1199, 2018 | 795 | 2018 |
| Molecular basis of bortezomib resistance: proteasome subunit β5 (PSMB5) gene mutation and overexpression of PSMB5 protein R Oerlemans, NE Franke, YG Assaraf, J Cloos, I van Zantwijk, CR Berkers, ... Blood, The Journal of the American Society of Hematology 112 (6), 2489-2499, 2008 | 541 | 2008 |
| Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia K De Keersmaecker, ZK Atak, N Li, C Vicente, S Patchett, T Girardi, ... Nature genetics 45 (2), 186-190, 2013 | 452 | 2013 |
| 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party M Heuser, SD Freeman, GJ Ossenkoppele, F Buccisano, CS Hourigan, ... Blood, The Journal of the American Society of Hematology 138 (26), 2753-2767, 2021 | 426 | 2021 |
| In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma SE Mir, PCDW Hamer, PM Krawczyk, L Balaj, A Claes, JM Niers, ... Cancer cell 18 (3), 244-257, 2010 | 311 | 2010 |
| Molecular signature associated with bone marrow micrometastasis in human breast cancer U Woelfle, J Cloos, G Sauter, L Riethdorf, F Jänicke, P Van Diest, ... Cancer research 63 (18), 5679-5684, 2003 | 287 | 2003 |
| miR-101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesis M Smits, J Nilsson, SE Mir, PM van der Stoop, E Hulleman, JM Niers, ... Oncotarget 1 (8), 710, 2010 | 278 | 2010 |
| Genetic susceptibility to head and neck squamous cell carcinoma J Cloos, MR Spitz, SP Schantz, TC Hsu, Z Zhang, H Tobi, BJM Braakhuis, ... JNCI: Journal of the National Cancer Institute 88 (8), 530-535, 1996 | 231 | 1996 |
| Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells NE Franke, D Niewerth, YG Assaraf, J van Meerloo, K Vojtekova, ... Leukemia 26 (4), 757-768, 2012 | 216 | 2012 |
| Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML IHIM Hollink, CM Zwaan, M Zimmermann, T Arentsen-Peters, R Pieters, ... Leukemia 23 (2), 262-270, 2009 | 207 | 2009 |
| Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples J Cloos, BF Goemans, CJ Hess, JW Van Oostveen, Q Waisfisz, S Corthals, ... Leukemia 20 (7), 1217-1220, 2006 | 206 | 2006 |
| The role of alternative splicing in cancer: From oncogenesis to drug resistance R Sciarrillo, A Wojtuszkiewicz, YG Assaraf, G Jansen, GJL Kaspers, ... Drug Resistance Updates 53, 100728, 2020 | 193 | 2020 |
| CD34+CD38− leukemic stem cell frequency to predict outcome in acute myeloid leukemia W Zeijlemaker, T Grob, R Meijer, D Hanekamp, A Kelder, ... Leukemia 33 (5), 1102-1112, 2019 | 193 | 2019 |
| The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia I Hubeek, RW Stam, GJ Peters, R Broekhuizen, JPP Meijerink, ... British journal of cancer 93 (12), 1388-1394, 2005 | 188 | 2005 |
| Molecular basis of resistance to proteasome inhibitors in hematological malignancies D Niewerth, G Jansen, YG Assaraf, S Zweegman, GJL Kaspers, J Cloos Drug resistance updates 18, 18-35, 2015 | 183 | 2015 |
| Comprehensive analysis of transcriptome variation uncovers known and novel driver events in T-cell acute lymphoblastic leukemia Z Kalender Atak, V Gianfelici, G Hulselmans, K De Keersmaecker, ... PLoS genetics 9 (12), e1003997, 2013 | 176 | 2013 |
| Bortezomib resistance in multiple myeloma is associated with increased serine synthesis EA Zaal, W Wu, G Jansen, S Zweegman, J Cloos, CR Berkers Cancer & metabolism 5, 1-12, 2017 | 162 | 2017 |
